{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:04Z","timestamp":1790657764930,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Incyte Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03673-6","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:32:23Z","timestamp":1783931543000},"page":"4602-4616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct04818346","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"Thierry","family":"Passeron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-2651","authenticated-orcid":false,"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-8195","authenticated-orcid":false,"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Erskine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-6047","authenticated-orcid":false,"given":"Leandro L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8196-2181","authenticated-orcid":false,"given":"Zhenyi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"6","key":"3673_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"issue":"7","key":"3673_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13555-022-00752-8","volume":"12","author":"H Kitchen","year":"2022","unstructured":"Kitchen H, Wyrwich KW, Carmichael C, et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol Ther (Heidelb). 2022;12(7):1623\u201337.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"3673_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18\u201329.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3673_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-0781.2012.00648.x","volume":"28","author":"Z Hallaji","year":"2012","unstructured":"Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012;28(3):115\u20139.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"9","key":"3673_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1468-3083.2011.04215.x","volume":"26","author":"SM Esmat","year":"2012","unstructured":"Esmat SM, El-Tawdy AM, Hafez GA, et al. Acral lesions of vitiligo: why are they resistant to photochemotherapy? J Eur Acad Dermatol Venereol. 2012;26(9):1097\u2013104.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3673_CR6","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1111\/jdv.20236","volume":"39","author":"T Passeron","year":"2025","unstructured":"Passeron T, Harris JE, Pandya AG, et al. Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeks. J Eur Acad Dermatol Venereol. 2025;39(3):e251\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3673_CR7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaad.2025.06.027","volume":"93","author":"AG Pandya","year":"2025","unstructured":"Pandya AG, Ezzedine K, Passeron T, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2025;93(4):946\u201355.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3673_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bjd.19422","volume":"184","author":"VS Narayan","year":"2021","unstructured":"Narayan VS, Uitentuis SE, Bekkenk MW, Wolkerstorfer A. What is successful repigmentation in vitiligo from the point of view of patients? Br J Dermatol. 2021;184(1):165\u20136.","journal-title":"Br J Dermatol"},{"issue":"6","key":"3673_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.jaad.2021.05.047","volume":"86","author":"I Hamzavi","year":"2022","unstructured":"Hamzavi I, Rosmarin D, Harris JE, et al. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double-blind trial. J Am Acad Dermatol. 2022;86(6):1398\u2013401.","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"3673_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"3673_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/jdpa.0000000000000041","volume":"19","author":"J McElroy","year":"2025","unstructured":"McElroy J, Casquejo RJ, Yu H, et al. Understanding the mechanism of disease of vitiligo and the impact on clinical management. J Dermatol Physician Assist. 2025;19(1):28\u201335.","journal-title":"J Dermatol Physician Assist"},{"issue":"2","key":"3673_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.det.2016.11.015","volume":"35","author":"SA Birlea","year":"2017","unstructured":"Birlea SA, Goldstein NB, Norris DA. Repigmentation through melanocyte regeneration in vitiligo. Dermatol Clin. 2017;35(2):205\u201318.","journal-title":"Dermatol Clin"},{"key":"3673_CR13","doi-asserted-by":"publisher","first-page":"1511053","DOI":"10.3389\/fresc.2024.1511053","volume":"5","author":"Y Valle","year":"2025","unstructured":"Valle Y, Lotti T, Towheed S, Sigova J. Mapping the vitiligo patient journey: from awareness to treatment or coping strategies. Front Rehabil Sci. 2025;5:1511053.","journal-title":"Front Rehabil Sci"},{"issue":"1","key":"3673_CR14","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/s41598-025-89346-w","volume":"15","author":"H Feng","year":"2025","unstructured":"Feng H, Xu X, Qi S, et al. Knowledge, attitude, and practice toward vitiligo among vitiligo patients: a mediation analysis. Sci Rep. 2025;15(1):4741.","journal-title":"Sci Rep"},{"issue":"1","key":"3673_CR15","doi-asserted-by":"publisher","first-page":"2483808","DOI":"10.1080\/09546634.2025.2483808","volume":"36","author":"L Luo","year":"2025","unstructured":"Luo L, Huang J, Fu C, et al. The efficacy of combined phototherapy with topical therapy in vitiligo: a network meta-analysis. J Dermatolog Treat. 2025;36(1):2483808.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"3673_CR16","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","volume":"142","author":"AG Pandya","year":"2022","unstructured":"Pandya AG, Harris JE, Lebwohl M, et al. Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo. J Invest Dermatol. 2022;142(12):3352-3355.e4.","journal-title":"J Invest Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03673-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03673-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03673-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:16:01Z","timestamp":1790655361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03673-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3673"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03673-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thierry Passeron has received grants and\/or honoraria from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Clinuvel, Galderma, Genzyme\/Sanofi, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sun Pharmaceuticals, Takeda, UCB, and Vyne Therapeutics; is the cofounder of NIKAIA Pharmaceuticals; and has patents on WNT agonists or GSK3b antagonist for repigmentation of vitiligo and on the use of CXCR3B blockers in vitiligo. Amit G. Pandya has served as an investigator for Avita, Clinuvel, and Incyte; a consultant for AbbVie, Avita, Boehringer Ingelheim, Incyte, Lilly, Pfizer, Sun Pharma, Thalocan, Villaris, Vimela, Vyne, and WCG; and has partial ownership of Tara Medical. Khaled Ezzedine is a consultant for AbbVie, Almirall, Bristol Myers Squibb, Incyte Corporation, La Roche-Posay, Lilly, Pfizer, Pierre Fabre, and Sanofi. Nanja van Geel received grants and\/or is a consultant and\/or investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Idorsia Pharmaceuticals, Incyte, Merck\/MSD, Novartis, Pfizer, and Takeda; and is chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology (EADV). Lois Erskine, Leandro L. Santos, and Zhenyi Xue are employees and shareholders of Incyte. Andrew Blauvelt has served as a speaker (received honoraria) for Almirall, Eli Lilly, LEO Pharma, Sanofi, and UCB; has served as a scientific advisor (received honoraria) for AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Eli Lilly, Incyte, Janssen, Khanda Therapeutics, LEO Pharma, Novartis, Oruka, Pfizer, Re-AIM, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was carried out in accordance with the Declaration of Helsinki, study protocol, applicable Good Clinical Practice, and local regulatory requirements. An institutional review board or independent ethics committee approved the study protocol and amendments at each site. All patients provided written informed consent before participating in the trial, including for publication of clinical photos.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}